ID   CD36_HUMAN              Reviewed;         472 AA.
AC   P16671; D9IX66; D9IX67; D9IX68; D9IX69; Q13966; Q16093; Q8TCV7;
AC   Q9BPZ8; Q9BQC2; Q9BZM8; Q9BZN3; Q9BZN4; Q9BZN5;
DT   01-AUG-1990, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 2.
DT   10-MAY-2017, entry version 188.
DE   RecName: Full=Platelet glycoprotein 4;
DE   AltName: Full=Fatty acid translocase;
DE            Short=FAT;
DE   AltName: Full=Glycoprotein IIIb;
DE            Short=GPIIIB;
DE   AltName: Full=Leukocyte differentiation antigen CD36;
DE   AltName: Full=PAS IV;
DE   AltName: Full=PAS-4;
DE   AltName: Full=Platelet collagen receptor;
DE   AltName: Full=Platelet glycoprotein IV;
DE            Short=GPIV;
DE   AltName: Full=Thrombospondin receptor;
DE   AltName: CD_antigen=CD36;
GN   Name=CD36; Synonyms=GP3B, GP4;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Placenta;
RX   PubMed=2473841; DOI=10.1016/0092-8674(89)90406-6;
RA   Oquendo P., Hundt E., Lawler J., Seed B.;
RT   "CD36 directly mediates cytoadherence of Plasmodium falciparum
RT   parasitized erythrocytes.";
RL   Cell 58:95-101(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Sugimoto Y., Tsuruo T.;
RL   Submitted (AUG-1992) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=7693552; DOI=10.1016/0378-1119(93)90639-K;
RA   Taylor K.T., Tang Y., Sobieski D.A., Lipsky R.H.;
RT   "Characterization of two alternatively spliced 5'-untranslated exons
RT   of the human CD36 gene in different cell types.";
RL   Gene 133:205-212(1993).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Platelet;
RX   PubMed=7505064;
RA   Wyler B., Daviet L., Bortkiewicz H., Bordet J.C., McGregor J.L.;
RT   "Cloning of the cDNA encoding human platelet CD36: comparison to PCR
RT   amplified fragments of monocyte, endothelial and HEL cells.";
RL   Thromb. Haemost. 70:500-505(1993).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=7518447;
RA   Armesilla A.L., Vega M.A.;
RT   "Structural organization of the gene for human CD36 glycoprotein.";
RL   J. Biol. Chem. 269:18985-18991(1994).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   SeattleSNPs variation discovery resource;
RL   Submitted (JAN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2; 3 AND 4), AND VARIANTS
RP   TRP-386 AND ILE-470.
RA   Wu G.-G., Curtis B.R., He B.-R., Zhou Z.-L., Zhou Y., Yang Y.-L.,
RA   Li H.-Y., Shen W.-D., Liu J.-L., Zhao T.-M.;
RT   "Frequency of CD36 deficiency and identification of novel CD36 gene
RT   mutations in the Chinese population.";
RL   Submitted (MAY-2010) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12853948; DOI=10.1038/nature01782;
RA   Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H.,
RA   Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R.,
RA   Wylie K., Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H.,
RA   Sun H., Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A.,
RA   Vanbrunt A., Nguyen C., Du F., Lamar B., Courtney L., Kalicki J.,
RA   Ozersky P., Bielicki L., Scott K., Holmes A., Harkins R., Harris A.,
RA   Strong C.M., Hou S., Tomlinson C., Dauphin-Kohlberg S.,
RA   Kozlowicz-Reilly A., Leonard S., Rohlfing T., Rock S.M.,
RA   Tin-Wollam A.-M., Abbott A., Minx P., Maupin R., Strowmatt C.,
RA   Latreille P., Miller N., Johnson D., Murray J., Woessner J.P.,
RA   Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W., Spieth J.,
RA   Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E., Cook L.L.,
RA   Hickenbotham M.T., Eldred J., Williams D., Bedell J.A., Mardis E.R.,
RA   Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E.,
RA   Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K.,
RA   Simms E., Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S.,
RA   Baertsch R.A., Brent M.R., Keibler E., Flicek P., Bork P., Suyama M.,
RA   Bailey J.A., Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R.,
RA   Eddy S.R., McPherson J.D., Olson M.V., Eichler E.E., Green E.D.,
RA   Waterston R.H., Wilson R.K.;
RT   "The DNA sequence of human chromosome 7.";
RL   Nature 424:157-164(2003).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Skeletal muscle;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   PROTEIN SEQUENCE OF 2-37, AND GLYCOSYLATION.
RC   TISSUE=Platelet;
RX   PubMed=2468669;
RA   Tandon N.N., Lipsky R.H., Burgess W.H., Jamieson G.A.;
RT   "Isolation and characterization of platelet glycoprotein IV (CD36).";
RL   J. Biol. Chem. 264:7570-7575(1989).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 41-203; 274-375 AND 419-472, AND
RP   VARIANTS LYS-123; ALA-174; ASN-232 INS AND THR-271.
RX   PubMed=11668637; DOI=10.1002/humu.1215;
RA   Gelhaus A., Scheding A., Browne E., Burchard G.D., Horstmann R.D.;
RT   "Variability of the CD36 gene in West Africa.";
RL   Hum. Mutat. 18:444-450(2001).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 144-203 (ISOFORM 1/2).
RX   PubMed=7503937; DOI=10.1006/geno.1993.1401;
RA   Fernandez-Ruiz E., Armesilla A.L., Sanchez-Madrid F., Vega M.A.;
RT   "Gene encoding the collagen type I and thrombospondin receptor CD36 is
RT   located on chromosome 7q11.2.";
RL   Genomics 17:759-761(1993).
RN   [13]
RP   PROTEIN SEQUENCE OF 261-273 AND 369-385.
RC   TISSUE=Adipocyte;
RX   PubMed=15242332; DOI=10.1042/BJ20040647;
RA   Aboulaich N., Vainonen J.P., Stralfors P., Vener A.V.;
RT   "Vectorial proteomics reveal targeting, phosphorylation and specific
RT   fragmentation of polymerase I and transcript release factor (PTRF) at
RT   the surface of caveolae in human adipocytes.";
RL   Biochem. J. 383:237-248(2004).
RN   [14]
RP   INTERACTION WITH THBS1 AND THBS2.
RX   PubMed=1371676; DOI=10.1016/0006-291X(92)91860-S;
RA   Asch A.S., Silbiger S., Heimer E., Nachman R.L.;
RT   "Thrombospondin sequence motif (CSVTCG) is responsible for CD36
RT   binding.";
RL   Biochem. Biophys. Res. Commun. 182:1208-1217(1992).
RN   [15]
RP   PALMITOYLATION AT CYS-3; CYS-7; CYS-464 AND CYS-466.
RX   PubMed=8798390; DOI=10.1074/jbc.271.37.22315;
RA   Tao N., Wagner S.J., Lublin D.M.;
RT   "CD36 is palmitoylated on both N- and C-terminal cytoplasmic tails.";
RL   J. Biol. Chem. 271:22315-22320(1996).
RN   [16]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH TLR2 AND TLR6.
RX   PubMed=16880211; DOI=10.1074/jbc.M602794200;
RA   Triantafilou M., Gamper F.G., Haston R.M., Mouratis M.A., Morath S.,
RA   Hartung T., Triantafilou K.;
RT   "Membrane sorting of toll-like receptor (TLR)-2/6 and TLR2/1
RT   heterodimers at the cell surface determines heterotypic associations
RT   with CD36 and intracellular targeting.";
RL   J. Biol. Chem. 281:31002-31011(2006).
RN   [17]
RP   FUNCTION, UBIQUITINATION AT LYS-469 AND LYS-472, AND MUTAGENESIS OF
RP   469-LYS--LYS-472.
RX   PubMed=18353783; DOI=10.1074/jbc.M800008200;
RA   Smith J., Su X., El-Maghrabi R., Stahl P.D., Abumrad N.A.;
RT   "Opposite regulation of CD36 ubiquitination by fatty acids and
RT   insulin: effects on fatty acid uptake.";
RL   J. Biol. Chem. 283:13578-13585(2008).
RN   [18]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-417.
RC   TISSUE=Platelet;
RX   PubMed=16263699; DOI=10.1074/mcp.M500324-MCP200;
RA   Lewandrowski U., Moebius J., Walter U., Sickmann A.;
RT   "Elucidation of N-glycosylation sites on human platelet proteins: a
RT   glycoproteomic approach.";
RL   Mol. Cell. Proteomics 5:226-233(2006).
RN   [19]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-321.
RC   TISSUE=Milk;
RX   PubMed=18780401; DOI=10.1002/pmic.200701057;
RA   Picariello G., Ferranti P., Mamone G., Roepstorff P., Addeo F.;
RT   "Identification of N-linked glycoproteins in human milk by hydrophilic
RT   interaction liquid chromatography and mass spectrometry.";
RL   Proteomics 8:3833-3847(2008).
RN   [20]
RP   FUNCTION (MICROBIAL INFECTION).
RX   PubMed=19864601; DOI=10.4049/jimmunol.0901374;
RA   Erdman L.K., Cosio G., Helmers A.J., Gowda D.C., Grinstein S.,
RA   Kain K.C.;
RT   "CD36 and TLR interactions in inflammation and phagocytosis:
RT   implications for malaria.";
RL   J. Immunol. 183:6452-6459(2009).
RN   [21]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-205 AND ASN-417.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [22]
RP   REVIEW OF FUNCTION.
RX   PubMed=19471024; DOI=10.1126/scisignal.272re3;
RA   Silverstein R.L., Febbraio M.;
RT   "CD36, a scavenger receptor involved in immunity, metabolism,
RT   angiogenesis, and behavior.";
RL   Sci. Signal. 2:RE3-RE3(2009).
RN   [23]
RP   FUNCTION, INTERACTION WITH LYN; PTK2; PXN; TLR4 AND TLR6, SUBCELLULAR
RP   LOCATION, AND MUTAGENESIS OF 462-SER--LYS-473; TYR-463 AND CYS-464.
RX   PubMed=20037584; DOI=10.1038/ni.1836;
RA   Stewart C.R., Stuart L.M., Wilkinson K., van Gils J.M., Deng J.,
RA   Halle A., Rayner K.J., Boyer L., Zhong R., Frazier W.A.,
RA   Lacy-Hulbert A., El Khoury J., Golenbock D.T., Moore K.J.;
RT   "CD36 ligands promote sterile inflammation through assembly of a Toll-
RT   like receptor 4 and 6 heterodimer.";
RL   Nat. Immunol. 11:155-161(2010).
RN   [24]
RP   FUNCTION, UBIQUITINATION AT LYS-469 AND LYS-472, AND MUTAGENESIS OF
RP   469-LYS--LYS-472.
RX   PubMed=21610069; DOI=10.1074/jbc.M111.233551;
RA   Tran T.T., Poirier H., Clement L., Nassir F., Pelsers M.M., Petit V.,
RA   Degrace P., Monnot M.C., Glatz J.F., Abumrad N.A., Besnard P.,
RA   Niot I.;
RT   "Luminal lipid regulates CD36 levels and downstream signaling to
RT   stimulate chylomicron synthesis.";
RL   J. Biol. Chem. 286:25201-25210(2011).
RN   [25]
RP   FUNCTION.
RX   PubMed=22240721; DOI=10.1038/oby.2011.374;
RA   Keller K.L., Liang L.C., Sakimura J., May D., van Belle C., Breen C.,
RA   Driggin E., Tepper B.J., Lanzano P.C., Deng L., Chung W.K.;
RT   "Common variants in the CD36 gene are associated with oral fat
RT   perception, fat preferences, and obesity in African Americans.";
RL   Obesity 20:1066-1073(2012).
RN   [26]
RP   FUNCTION.
RX   PubMed=25822988; DOI=10.1017/S0007114515000343;
RA   Mrizak I., Sery O., Plesnik J., Arfa A., Fekih M., Bouslema A.,
RA   Zaouali M., Tabka Z., Khan N.A.;
RT   "The A allele of cluster of differentiation 36 (CD36) SNP 1761667
RT   associates with decreased lipid taste perception in obese Tunisian
RT   women.";
RL   Br. J. Nutr. 113:1330-1337(2015).
RN   [27]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [28]
RP   VARIANT PG4D SER-90.
RX   PubMed=7533783; DOI=10.1172/JCI117749;
RA   Kashiwagi H., Tomiyama Y., Honda S., Kosugi S., Shiraga M., Nagao N.,
RA   Sekiguchi S., Kanayama Y., Kurata Y., Matsuzawa Y.;
RT   "Molecular basis of CD36 deficiency. Evidence that a 478C-->T
RT   substitution (proline90-->serine) in CD36 cDNA accounts for CD36
RT   deficiency.";
RL   J. Clin. Invest. 95:1040-1046(1995).
RN   [29]
RP   VARIANT PHE-154.
RX   PubMed=10391209; DOI=10.1038/10290;
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RT   "Characterization of single-nucleotide polymorphisms in coding regions
RT   of human genes.";
RL   Nat. Genet. 22:231-238(1999).
RN   [30]
RP   ERRATUM.
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RL   Nat. Genet. 23:373-373(1999).
RN   [31]
RP   ROLE IN MALARIA INFECTION.
RX   PubMed=10890433; DOI=10.1038/35016636;
RA   Aitman T.J., Cooper L.D., Norsworthy P.J., Wahid F.N., Gray J.K.,
RA   Curtis B.R., McKeigue P.M., Kwiatkowski D., Greenwood B.M., Snow R.W.,
RA   Hill A.V., Scott J.;
RT   "Malaria susceptibility and CD36 mutation.";
RL   Nature 405:1015-1016(2000).
RN   [32]
RP   VARIANTS PG4D SER-90; LEU-254 AND LEU-413.
RX   PubMed=11950861; DOI=10.1136/jmg.39.4.286;
RA   Hanawa H., Watanabe K., Nakamura T., Ogawa Y., Toba K., Fuse I.,
RA   Kodama M., Kato K., Fuse K., Aizawa Y.;
RT   "Identification of cryptic splice site, exon skipping, and novel point
RT   mutations in type I CD36 deficiency.";
RL   J. Med. Genet. 39:286-291(2002).
RN   [33]
RP   VARIANT LEU-127, AND ROLE IN MALARIA INFECTION.
RX   PubMed=12506336; DOI=10.1086/346091;
RA   Omi K., Ohashi J., Patarapotikul J., Hananantachai H., Naka I.,
RA   Looareesuwan S., Tokunaga K.;
RT   "CD36 polymorphism is associated with protection from cerebral
RT   malaria.";
RL   Am. J. Hum. Genet. 72:364-374(2003).
RN   [34]
RP   INVOLVEMENT IN CHDS7.
RX   PubMed=15282206; DOI=10.1093/hmg/ddh233;
RA   Ma X., Bacci S., Mlynarski W., Gottardo L., Soccio T., Menzaghi C.,
RA   Iori E., Lager R.A., Shroff A.R., Gervino E.V., Nesto R.W.,
RA   Johnstone M.T., Abumrad N.A., Avogaro A., Trischitta V., Doria A.;
RT   "A common haplotype at the CD36 locus is associated with high free
RT   fatty acid levels and increased cardiovascular risk in Caucasians.";
RL   Hum. Mol. Genet. 13:2197-2205(2004).
RN   [35]
RP   ERRATUM.
RA   Ma X., Bacci S., Mlynarski W., Gottardo L., Soccio T., Menzaghi C.,
RA   Iori E., Lager R.A., Shroff A.R., Gervino E.V., Nesto R.W.,
RA   Johnstone M.T., Abumrad N.A., Avogaro A., Trischitta V., Doria A.;
RL   Hum. Mol. Genet. 14:3973-3973(2005).
RN   [36]
RP   INVOLVEMENT IN PG4D, AND FUNCTION.
RX   PubMed=18753675; DOI=10.1194/jlr.P700032-JLR200;
RA   Masuda D., Hirano K., Oku H., Sandoval J.C., Kawase R.,
RA   Yuasa-Kawase M., Yamashita Y., Takada M., Tsubakio-Yamamoto K.,
RA   Tochino Y., Koseki M., Matsuura F., Nishida M., Kawamoto T.,
RA   Ishigami M., Hori M., Shimomura I., Yamashita S.;
RT   "Chylomicron remnants are increased in the postprandial state in CD36
RT   deficiency.";
RL   J. Lipid Res. 50:999-1011(2009).
RN   [37] {ECO:0000244|PDB:5LGD}
RP   X-RAY CRYSTALLOGRAPHY (2.07 ANGSTROMS), AND INTERACTION WITH
RP   PLASMODIUM FALCIPARUM EMP1.
RX   PubMed=27667267; DOI=10.1038/ncomms12837;
RA   Hsieh F.L., Turner L., Bolla J.R., Robinson C.V., Lavstsen T.,
RA   Higgins M.K.;
RT   "The structural basis for CD36 binding by the malaria parasite.";
RL   Nat. Commun. 7:12837-12837(2016).
CC   -!- FUNCTION: Multifunctional glycoprotein that acts as receptor for a
CC       broad range of ligands. Ligands can be of proteinaceous nature
CC       like thrombospondin, fibronectin, collagen or amyloid-beta as well
CC       as of lipidic nature such as oxidized low-density lipoprotein
CC       (oxLDL), anionic phospholipids, long-chain fatty acids and
CC       bacterial diacylated lipopeptides. They are generally multivalent
CC       and can therefore engage multiple receptors simultaneously, the
CC       resulting formation of CD36 clusters initiates signal transduction
CC       and internalization of receptor-ligand complexes. The dependency
CC       on coreceptor signaling is strongly ligand specific. Cellular
CC       responses to these ligands are involved in angiogenesis,
CC       inflammatory response, fatty acid metabolism, taste and dietary
CC       fat processing in the intestine (Probable). Binds long-chain fatty
CC       acids and facilitates their transport into cells, thus
CC       participating in muscle lipid utilization, adipose energy storage,
CC       and gut fat absorption (By similarity) (PubMed:18353783,
CC       PubMed:21610069). In the small intestine, plays a role in proximal
CC       absorption of dietary fatty acid and cholesterol for optimal
CC       chylomicron formation, possibly through the activation of MAPK1/3
CC       (ERK1/2) signaling pathway (By similarity) (PubMed:18753675).
CC       Involved in oral fat perception and preferences (PubMed:22240721,
CC       PubMed:25822988). Detection into the tongue of long-chain fatty
CC       acids leads to a rapid and sustained rise in flux and protein
CC       content of pancreatobiliary secretions (By similarity). In taste
CC       receptor cells, mediates the induction of an increase in
CC       intracellular calcium levels by long-chain fatty acids, leading to
CC       the activation of the gustatory neurons in the nucleus of the
CC       solitary tract (By similarity). Important factor in both
CC       ventromedial hypothalamus neuronal sensing of long-chain fatty
CC       acid and the regulation of energy and glucose homeostasis (By
CC       similarity). Receptor for thombospondins, THBS1 and THBS2,
CC       mediating their antiangiogenic effects (By similarity). As a
CC       coreceptor for TLR4:TLR6 heterodimer, promotes inflammation in
CC       monocytes/macrophages. Upon ligand binding, such as oxLDL or
CC       amyloid-beta 42, interacts with the heterodimer TLR4:TLR6, the
CC       complex is internalized and triggers inflammatory response,
CC       leading to NF-kappa-B-dependent production of CXCL1, CXCL2 and
CC       CCL9 cytokines, via MYD88 signaling pathway, and CCL5 cytokine,
CC       via TICAM1 signaling pathway, as well as IL1B secretion, through
CC       the priming and activation of the NLRP3 inflammasome (By
CC       similarity) (PubMed:20037584). Selective and nonredundant sensor
CC       of microbial diacylated lipopeptide that signal via TLR2:TLR6
CC       heterodimer, this cluster triggers signaling from the cell
CC       surface, leading to the NF-kappa-B-dependent production of TNF,
CC       via MYD88 signaling pathway and subsequently is targeted to the
CC       Golgi in a lipid-raft dependent pathway (By similarity)
CC       (PubMed:16880211). {ECO:0000250|UniProtKB:Q07969,
CC       ECO:0000250|UniProtKB:Q08857, ECO:0000269|PubMed:16880211,
CC       ECO:0000269|PubMed:18353783, ECO:0000269|PubMed:18753675,
CC       ECO:0000269|PubMed:20037584, ECO:0000269|PubMed:21610069,
CC       ECO:0000269|PubMed:22240721, ECO:0000269|PubMed:25822988,
CC       ECO:0000305|PubMed:19471024}.
CC   -!- FUNCTION: (Microbial infection) Directly mediates cytoadherence of
CC       Plasmodium falciparum parasitized erythrocytes and the
CC       internalization of particles independently of TLR signaling.
CC       {ECO:0000269|PubMed:10890433, ECO:0000269|PubMed:12506336,
CC       ECO:0000269|PubMed:19864601}.
CC   -!- SUBUNIT: Interacts with THBS1 and THBS2; the interactions mediate
CC       the THBS antiangiogenic activity (PubMed:1371676). Upon
CC       interaction with a ligand, such as oxidized low-density
CC       lipoprotein (oxLDL) or amyloid-beta 42, rapidly forms a complex
CC       with TLR4 and TLR6; the complex is internalized and triggers an
CC       inflammatory signal. Through its C-terminus, interacts with PTK2,
CC       PXN and LYN, but not with SRC. LYN kinase activity is required for
CC       facilitating TLR4:TLR6 heterodimerization and signal initiation
CC       (PubMed:1371676, PubMed:20037584). Upon interaction with ligands
CC       such as diacylated lipopeptides, interacts with the TLR2:TLR6
CC       heterodimer (PubMed:16880211). Interacts with CD9, CD81, FCER1G,
CC       ITGB2 and/or ITGB2; forming a membrane heteromeric complex
CC       required for the internalization of CD36 and its ligands (By
CC       similarity). {ECO:0000250|UniProtKB:Q08857,
CC       ECO:0000269|PubMed:1371676, ECO:0000269|PubMed:16880211,
CC       ECO:0000269|PubMed:20037584}.
CC   -!- SUBUNIT: (Microbial infection) Binds to Plasmodium falciparum
CC       EMP1. {ECO:0000269|PubMed:27667267}.
CC   -!- INTERACTION:
CC       P07996:THBS1; NbExp=2; IntAct=EBI-2808214, EBI-13915509;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:16880211};
CC       Multi-pass membrane protein {ECO:0000255}. Membrane raft
CC       {ECO:0000269|PubMed:16880211}. Golgi apparatus
CC       {ECO:0000269|PubMed:16880211}. Apical cell membrane
CC       {ECO:0000250|UniProtKB:Q08857}. Note=Upon ligand-binding,
CC       internalized through dynamin-dependent endocytosis.
CC       {ECO:0000269|PubMed:20037584}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=P16671-1; Sequence=Displayed;
CC       Name=2; Synonyms=ex8-del;
CC         IsoId=P16671-2; Sequence=VSP_055978, VSP_055979;
CC       Name=3; Synonyms=ex6-7-del;
CC         IsoId=P16671-3; Sequence=VSP_055977;
CC       Name=4; Synonyms=ex4-del;
CC         IsoId=P16671-4; Sequence=VSP_055976;
CC   -!- PTM: N-glycosylated and O-glycosylated with a ratio of 2:1.
CC       {ECO:0000269|PubMed:16263699, ECO:0000269|PubMed:18780401,
CC       ECO:0000269|PubMed:19159218, ECO:0000269|PubMed:2468669}.
CC   -!- PTM: Ubiquitinated at Lys-469 and Lys-472. Ubiquitination is
CC       induced by fatty acids such as oleic acid and leads to degradation
CC       by the proteasome (PubMed:21610069, PubMed:18353783).
CC       Ubiquitination and degradation are inhibited by insulin which
CC       blocks the effect of fatty acids (PubMed:18353783).
CC       {ECO:0000269|PubMed:18353783, ECO:0000269|PubMed:21610069}.
CC   -!- POLYMORPHISM: Genetic variations in CD36 are involved in
CC       susceptibility to malaria and influence the severity and outcome
CC       of malaria infection [MIM:611162].
CC   -!- DISEASE: Platelet glycoprotein IV deficiency (PG4D) [MIM:608404]:
CC       A disorder characterized by macrothrombocytopenia without notable
CC       hemostatic problems and bleeding tendency. Platelet glycoprotein
CC       IV deficiency can be divided into 2 subgroups. The type I
CC       phenotype is characterized by platelets and monocytes/macrophages
CC       exhibiting complete CD36 deficiency. The type II phenotype lacks
CC       the surface expression of CD36 in platelets, but expression in
CC       monocytes/macrophages is near normal.
CC       {ECO:0000269|PubMed:11950861, ECO:0000269|PubMed:7533783}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry. Patients also have postprandial
CC       hypertriglyceridemia, insulin resistance and hypertension
CC       increasing atherosclerotic risk. {ECO:0000269|PubMed:18753675}.
CC   -!- DISEASE: Coronary heart disease 7 (CHDS7) [MIM:610938]: A
CC       multifactorial disease characterized by an imbalance between
CC       myocardial functional requirements and the capacity of the
CC       coronary vessels to supply sufficient blood flow. Decreased
CC       capacity of the coronary vessels is often associated with
CC       thickening and loss of elasticity of the coronary arteries.
CC       {ECO:0000269|PubMed:15282206}. Note=Disease susceptibility is
CC       associated with variations affecting the gene represented in this
CC       entry.
CC   -!- SIMILARITY: Belongs to the CD36 family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAM14636.2; Type=Frameshift; Positions=53; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=CD36 entry;
CC       URL="https://en.wikipedia.org/wiki/CD36";
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/cd36/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M24795; AAA35534.1; -; mRNA.
DR   EMBL; M98398; AAA58412.1; -; mRNA.
DR   EMBL; M98399; AAA58413.1; -; mRNA.
DR   EMBL; L06850; AAA16068.1; -; mRNA.
DR   EMBL; S67532; AAD13993.1; -; mRNA.
DR   EMBL; Z32770; CAA83662.1; -; Genomic_DNA.
DR   EMBL; Z32754; CAA83662.1; JOINED; Genomic_DNA.
DR   EMBL; Z32755; CAA83662.1; JOINED; Genomic_DNA.
DR   EMBL; Z32756; CAA83662.1; JOINED; Genomic_DNA.
DR   EMBL; Z32757; CAA83662.1; JOINED; Genomic_DNA.
DR   EMBL; Z32758; CAA83662.1; JOINED; Genomic_DNA.
DR   EMBL; Z32759; CAA83662.1; JOINED; Genomic_DNA.
DR   EMBL; Z32760; CAA83662.1; JOINED; Genomic_DNA.
DR   EMBL; Z32761; CAA83662.1; JOINED; Genomic_DNA.
DR   EMBL; Z32762; CAA83662.1; JOINED; Genomic_DNA.
DR   EMBL; Z32763; CAA83662.1; JOINED; Genomic_DNA.
DR   EMBL; Z32764; CAA83662.1; JOINED; Genomic_DNA.
DR   EMBL; AY095373; AAM14636.2; ALT_FRAME; Genomic_DNA.
DR   EMBL; HM217023; ADI80543.1; -; mRNA.
DR   EMBL; HM217024; ADI80544.1; -; mRNA.
DR   EMBL; HM217025; ADI80545.1; -; mRNA.
DR   EMBL; HM217026; ADI80546.1; -; mRNA.
DR   EMBL; AC004862; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC073182; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC073850; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC092108; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC124834; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC008406; AAH08406.1; -; mRNA.
DR   EMBL; AF300626; AAG60625.1; -; Genomic_DNA.
DR   EMBL; AF300627; AAG60626.1; -; Genomic_DNA.
DR   EMBL; AF300628; AAG60627.1; -; Genomic_DNA.
DR   EMBL; AF300633; AAG60632.1; -; Genomic_DNA.
DR   EMBL; AF300634; AAG60633.1; -; Genomic_DNA.
DR   EMBL; AF300635; AAG60634.1; -; Genomic_DNA.
DR   EMBL; AF300639; AAG60638.1; -; Genomic_DNA.
DR   EMBL; AF300640; AAG60639.1; -; Genomic_DNA.
DR   EMBL; S67044; AAB28992.1; -; mRNA.
DR   EMBL; Z22924; CAA80504.1; -; Genomic_DNA.
DR   CCDS; CCDS34673.1; -. [P16671-1]
DR   CCDS; CCDS78249.1; -. [P16671-3]
DR   CCDS; CCDS78250.1; -. [P16671-4]
DR   PIR; A54870; A54870.
DR   RefSeq; NP_000063.2; NM_000072.3. [P16671-1]
DR   RefSeq; NP_001001547.1; NM_001001547.2. [P16671-1]
DR   RefSeq; NP_001001548.1; NM_001001548.2. [P16671-1]
DR   RefSeq; NP_001120915.1; NM_001127443.1. [P16671-1]
DR   RefSeq; NP_001120916.1; NM_001127444.1. [P16671-1]
DR   RefSeq; NP_001276837.1; NM_001289908.1. [P16671-3]
DR   RefSeq; NP_001276838.1; NM_001289909.1. [P16671-4]
DR   RefSeq; NP_001276840.1; NM_001289911.1.
DR   RefSeq; XP_005250770.1; XM_005250713.1. [P16671-1]
DR   RefSeq; XP_005250771.1; XM_005250714.1. [P16671-1]
DR   RefSeq; XP_005250772.1; XM_005250715.4. [P16671-1]
DR   UniGene; Hs.120949; -.
DR   PDB; 5LGD; X-ray; 2.07 A; A=1-472.
DR   PDBsum; 5LGD; -.
DR   ProteinModelPortal; P16671; -.
DR   SMR; P16671; -.
DR   BioGrid; 107386; 19.
DR   IntAct; P16671; 8.
DR   STRING; 9606.ENSP00000308165; -.
DR   ChEMBL; CHEMBL1744526; -.
DR   SwissLipids; SLP:000001098; -.
DR   TCDB; 9.B.39.1.4; the long chain fatty acid translocase (lcfat) family.
DR   iPTMnet; P16671; -.
DR   PhosphoSitePlus; P16671; -.
DR   SwissPalm; P16671; -.
DR   BioMuta; CD36; -.
DR   DMDM; 115982; -.
DR   MaxQB; P16671; -.
DR   PaxDb; P16671; -.
DR   PeptideAtlas; P16671; -.
DR   PRIDE; P16671; -.
DR   DNASU; 948; -.
DR   Ensembl; ENST00000309881; ENSP00000308165; ENSG00000135218. [P16671-1]
DR   Ensembl; ENST00000394788; ENSP00000378268; ENSG00000135218. [P16671-1]
DR   Ensembl; ENST00000432207; ENSP00000411411; ENSG00000135218. [P16671-1]
DR   Ensembl; ENST00000433696; ENSP00000401863; ENSG00000135218. [P16671-3]
DR   Ensembl; ENST00000435819; ENSP00000399421; ENSG00000135218. [P16671-1]
DR   Ensembl; ENST00000447544; ENSP00000415743; ENSG00000135218. [P16671-1]
DR   Ensembl; ENST00000538969; ENSP00000439543; ENSG00000135218. [P16671-4]
DR   Ensembl; ENST00000544133; ENSP00000441956; ENSG00000135218. [P16671-2]
DR   GeneID; 948; -.
DR   KEGG; hsa:948; -.
DR   UCSC; uc003uhc.4; human. [P16671-1]
DR   CTD; 948; -.
DR   DisGeNET; 948; -.
DR   GeneCards; CD36; -.
DR   HGNC; HGNC:1663; CD36.
DR   HPA; CAB025866; -.
DR   HPA; HPA002018; -.
DR   MalaCards; CD36; -.
DR   MIM; 173510; gene.
DR   MIM; 248310; phenotype.
DR   MIM; 608404; phenotype.
DR   MIM; 610938; phenotype.
DR   MIM; 611162; phenotype.
DR   neXtProt; NX_P16671; -.
DR   OpenTargets; ENSG00000135218; -.
DR   PharmGKB; PA26212; -.
DR   eggNOG; KOG3776; Eukaryota.
DR   eggNOG; ENOG410XS17; LUCA.
DR   GeneTree; ENSGT00530000062927; -.
DR   HOVERGEN; HBG002754; -.
DR   InParanoid; P16671; -.
DR   KO; K06259; -.
DR   OMA; NTVSFLQ; -.
DR   OrthoDB; EOG091G0CH9; -.
DR   PhylomeDB; P16671; -.
DR   TreeFam; TF317925; -.
DR   Reactome; R-HSA-114608; Platelet degranulation.
DR   Reactome; R-HSA-1236973; Cross-presentation of particulate exogenous antigens (phagosomes).
DR   Reactome; R-HSA-1236974; ER-Phagosome pathway.
DR   Reactome; R-HSA-166058; MyD88:Mal cascade initiated on plasma membrane.
DR   Reactome; R-HSA-168188; Toll Like Receptor TLR6:TLR2 Cascade.
DR   Reactome; R-HSA-1989781; PPARA activates gene expression.
DR   Reactome; R-HSA-3000471; Scavenging by Class B Receptors.
DR   Reactome; R-HSA-381340; Transcriptional regulation of white adipocyte differentiation.
DR   Reactome; R-HSA-5602498; MyD88 deficiency (TLR2/4).
DR   Reactome; R-HSA-5603041; IRAK4 deficiency (TLR2/4).
DR   Reactome; R-HSA-5686938; Regulation of TLR by endogenous ligand.
DR   Reactome; R-HSA-6785807; Interleukin-4 and 13 signaling.
DR   Reactome; R-HSA-6798695; Neutrophil degranulation.
DR   ChiTaRS; CD36; human.
DR   GeneWiki; CD36; -.
DR   GenomeRNAi; 948; -.
DR   PRO; PR:P16671; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   Bgee; ENSG00000135218; -.
DR   ExpressionAtlas; P16671; baseline and differential.
DR   Genevisible; P16671; HS.
DR   GO; GO:0016324; C:apical plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0031526; C:brush border membrane; ISS:UniProtKB.
DR   GO; GO:0009986; C:cell surface; IDA:BHF-UCL.
DR   GO; GO:0030666; C:endocytic vesicle membrane; TAS:Reactome.
DR   GO; GO:0009897; C:external side of plasma membrane; IEA:Ensembl.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:BHF-UCL.
DR   GO; GO:0016020; C:membrane; TAS:ProtInc.
DR   GO; GO:0045121; C:membrane raft; IDA:UniProtKB.
DR   GO; GO:0045335; C:phagocytic vesicle; TAS:Reactome.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0031092; C:platelet alpha granule membrane; TAS:Reactome.
DR   GO; GO:0035579; C:specific granule membrane; TAS:Reactome.
DR   GO; GO:0008035; F:high-density lipoprotein particle binding; IEA:Ensembl.
DR   GO; GO:0008289; F:lipid binding; IDA:BHF-UCL.
DR   GO; GO:0071813; F:lipoprotein particle binding; IDA:UniProtKB.
DR   GO; GO:0070892; F:lipoteichoic acid receptor activity; IEA:Ensembl.
DR   GO; GO:0030169; F:low-density lipoprotein particle binding; IDA:BHF-UCL.
DR   GO; GO:0005041; F:low-density lipoprotein receptor activity; IMP:BHF-UCL.
DR   GO; GO:0070053; F:thrombospondin receptor activity; ISS:BHF-UCL.
DR   GO; GO:0050431; F:transforming growth factor beta binding; ISS:BHF-UCL.
DR   GO; GO:1990000; P:amyloid fibril formation; ISS:UniProtKB.
DR   GO; GO:0002479; P:antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent; TAS:Reactome.
DR   GO; GO:0043277; P:apoptotic cell clearance; IEA:Ensembl.
DR   GO; GO:0007596; P:blood coagulation; TAS:ProtInc.
DR   GO; GO:0007155; P:cell adhesion; TAS:ProtInc.
DR   GO; GO:0007166; P:cell surface receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0071726; P:cellular response to diacyl bacterial lipopeptide; IDA:UniProtKB.
DR   GO; GO:0071447; P:cellular response to hydroperoxide; IEA:Ensembl.
DR   GO; GO:0071222; P:cellular response to lipopolysaccharide; IEA:Ensembl.
DR   GO; GO:0071223; P:cellular response to lipoteichoic acid; IEA:Ensembl.
DR   GO; GO:0071404; P:cellular response to low-density lipoprotein particle stimulus; ISS:UniProtKB.
DR   GO; GO:0019934; P:cGMP-mediated signaling; IDA:BHF-UCL.
DR   GO; GO:0070508; P:cholesterol import; ISS:UniProtKB.
DR   GO; GO:0030301; P:cholesterol transport; ISS:BHF-UCL.
DR   GO; GO:0050830; P:defense response to Gram-positive bacterium; IEA:Ensembl.
DR   GO; GO:0050702; P:interleukin-1 beta secretion; ISS:UniProtKB.
DR   GO; GO:0050892; P:intestinal absorption; ISS:UniProtKB.
DR   GO; GO:0030299; P:intestinal cholesterol absorption; ISS:UniProtKB.
DR   GO; GO:0006629; P:lipid metabolic process; NAS:ProtInc.
DR   GO; GO:0019915; P:lipid storage; IMP:BHF-UCL.
DR   GO; GO:0042953; P:lipoprotein transport; IMP:BHF-UCL.
DR   GO; GO:0044539; P:long-chain fatty acid import; IDA:UniProtKB.
DR   GO; GO:0034383; P:low-density lipoprotein particle clearance; IMP:BHF-UCL.
DR   GO; GO:0055096; P:low-density lipoprotein particle mediated signaling; IEA:Ensembl.
DR   GO; GO:0002755; P:MyD88-dependent toll-like receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0044130; P:negative regulation of growth of symbiont in host; IEA:Ensembl.
DR   GO; GO:0042992; P:negative regulation of transcription factor import into nucleus; IEA:Ensembl.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IEA:Ensembl.
DR   GO; GO:0043312; P:neutrophil degranulation; TAS:Reactome.
DR   GO; GO:0007263; P:nitric oxide mediated signal transduction; IDA:BHF-UCL.
DR   GO; GO:0006910; P:phagocytosis, recognition; IEA:Ensembl.
DR   GO; GO:0034381; P:plasma lipoprotein particle clearance; ISS:BHF-UCL.
DR   GO; GO:0002576; P:platelet degranulation; TAS:Reactome.
DR   GO; GO:0030194; P:positive regulation of blood coagulation; IEA:Ensembl.
DR   GO; GO:2000334; P:positive regulation of blood microparticle formation; IEA:Ensembl.
DR   GO; GO:0001954; P:positive regulation of cell-matrix adhesion; IDA:BHF-UCL.
DR   GO; GO:0010886; P:positive regulation of cholesterol storage; IEA:Ensembl.
DR   GO; GO:0007204; P:positive regulation of cytosolic calcium ion concentration; ISS:UniProtKB.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; ISS:UniProtKB.
DR   GO; GO:0043123; P:positive regulation of I-kappaB kinase/NF-kappaB signaling; IEA:Ensembl.
DR   GO; GO:0032735; P:positive regulation of interleukin-12 production; IEA:Ensembl.
DR   GO; GO:0032755; P:positive regulation of interleukin-6 production; IEA:Ensembl.
DR   GO; GO:0060907; P:positive regulation of macrophage cytokine production; IEA:Ensembl.
DR   GO; GO:0010744; P:positive regulation of macrophage derived foam cell differentiation; IMP:BHF-UCL.
DR   GO; GO:1900227; P:positive regulation of NLRP3 inflammasome complex assembly; ISS:UniProtKB.
DR   GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; IEA:Ensembl.
DR   GO; GO:0060100; P:positive regulation of phagocytosis, engulfment; IEA:Ensembl.
DR   GO; GO:2000379; P:positive regulation of reactive oxygen species metabolic process; IEA:Ensembl.
DR   GO; GO:0032760; P:positive regulation of tumor necrosis factor production; IEA:Ensembl.
DR   GO; GO:0031623; P:receptor internalization; ISS:UniProtKB.
DR   GO; GO:0006898; P:receptor-mediated endocytosis; TAS:Reactome.
DR   GO; GO:2000505; P:regulation of energy homeostasis; ISS:UniProtKB.
DR   GO; GO:2000121; P:regulation of removal of superoxide radicals; IEA:Ensembl.
DR   GO; GO:0070542; P:response to fatty acid; ISS:UniProtKB.
DR   GO; GO:0070543; P:response to linoleic acid; ISS:UniProtKB.
DR   GO; GO:0033993; P:response to lipid; ISS:UniProtKB.
DR   GO; GO:0035634; P:response to stilbenoid; IEA:Ensembl.
DR   GO; GO:0050909; P:sensory perception of taste; ISS:UniProtKB.
DR   GO; GO:0002224; P:toll-like receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0038124; P:toll-like receptor TLR6:TLR2 signaling pathway; TAS:Reactome.
DR   GO; GO:0034197; P:triglyceride transport; ISS:UniProtKB.
DR   InterPro; IPR005428; CD36/SCARB1/SNMP1.
DR   InterPro; IPR033076; CD36_chordates.
DR   InterPro; IPR002159; CD36_fam.
DR   PANTHER; PTHR11923; PTHR11923; 1.
DR   PANTHER; PTHR11923:SF87; PTHR11923:SF87; 1.
DR   Pfam; PF01130; CD36; 1.
DR   PRINTS; PR01610; CD36ANTIGEN.
DR   PRINTS; PR01609; CD36FAMILY.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell adhesion; Cell membrane;
KW   Complete proteome; Direct protein sequencing; Disease mutation;
KW   Disulfide bond; Glycoprotein; Golgi apparatus; Isopeptide bond;
KW   Lipoprotein; Membrane; Palmitate; Polymorphism; Receptor;
KW   Reference proteome; Transmembrane; Transmembrane helix; Transport;
KW   Ubl conjugation.
FT   INIT_MET      1      1       Removed. {ECO:0000269|PubMed:2468669}.
FT   CHAIN         2    472       Platelet glycoprotein 4.
FT                                /FTId=PRO_0000144151.
FT   TOPO_DOM      2      7       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM      8     29       Helical. {ECO:0000255}.
FT   TOPO_DOM     30    439       Extracellular. {ECO:0000255}.
FT   TRANSMEM    440    461       Helical. {ECO:0000255}.
FT   TOPO_DOM    462    472       Cytoplasmic. {ECO:0000255}.
FT   REGION       93    120       Required for interaction with
FT                                thrombospondins, THBS1 and THBS2.
FT                                {ECO:0000269|PubMed:1371676}.
FT   REGION      460    472       Interaction with PTK2, PXN and LYN.
FT                                {ECO:0000269|PubMed:20037584}.
FT   SITE        463    463       Critical for TLR4-TLR6 dimerization and
FT                                signaling. {ECO:0000269|PubMed:20037584}.
FT   LIPID         3      3       S-palmitoyl cysteine.
FT                                {ECO:0000269|PubMed:8798390}.
FT   LIPID         7      7       S-palmitoyl cysteine.
FT                                {ECO:0000269|PubMed:8798390}.
FT   LIPID       464    464       S-palmitoyl cysteine.
FT                                {ECO:0000269|PubMed:8798390}.
FT   LIPID       466    466       S-palmitoyl cysteine.
FT                                {ECO:0000269|PubMed:8798390}.
FT   CARBOHYD     79     79       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    102    102       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    134    134       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    163    163       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    205    205       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:19159218}.
FT   CARBOHYD    220    220       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    235    235       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    247    247       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    321    321       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:18780401}.
FT   CARBOHYD    417    417       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:16263699,
FT                                ECO:0000269|PubMed:19159218}.
FT   DISULFID    243    311       {ECO:0000250}.
FT   DISULFID    272    333       {ECO:0000250}.
FT   DISULFID    313    322       {ECO:0000250}.
FT   CROSSLNK    469    469       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000305|PubMed:18353783,
FT                                ECO:0000305|PubMed:21610069}.
FT   CROSSLNK    472    472       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000305|PubMed:18353783,
FT                                ECO:0000305|PubMed:21610069}.
FT   VAR_SEQ     144    203       Missing (in isoform 4).
FT                                {ECO:0000303|Ref.7}.
FT                                /FTId=VSP_055976.
FT   VAR_SEQ     234    272       Missing (in isoform 3).
FT                                {ECO:0000303|Ref.7}.
FT                                /FTId=VSP_055977.
FT   VAR_SEQ     274    288       SIYAVFESDVNLKGI -> ETCVHFTSSFSVCKS (in
FT                                isoform 2). {ECO:0000303|Ref.7}.
FT                                /FTId=VSP_055978.
FT   VAR_SEQ     289    472       Missing (in isoform 2).
FT                                {ECO:0000303|Ref.7}.
FT                                /FTId=VSP_055979.
FT   VARIANT      90     90       P -> S (in PG4D; type I; degradation in
FT                                the cytoplasm due to defects in
FT                                maturation; dbSNP:rs3765187).
FT                                {ECO:0000269|PubMed:11950861,
FT                                ECO:0000269|PubMed:7533783}.
FT                                /FTId=VAR_017913.
FT   VARIANT     123    123       E -> K (in individuals from a malaria
FT                                endemic area in West Africa;
FT                                dbSNP:rs183461468).
FT                                {ECO:0000269|PubMed:11668637}.
FT                                /FTId=VAR_017914.
FT   VARIANT     127    127       S -> L (in dbSNP:rs201765331).
FT                                {ECO:0000269|PubMed:12506336}.
FT                                /FTId=VAR_019049.
FT   VARIANT     154    154       V -> F (in dbSNP:rs5957).
FT                                {ECO:0000269|PubMed:10391209}.
FT                                /FTId=VAR_013918.
FT   VARIANT     174    174       T -> A (in individuals from a malaria
FT                                endemic area in West Africa;
FT                                dbSNP:rs756525492).
FT                                {ECO:0000269|PubMed:11668637}.
FT                                /FTId=VAR_017915.
FT   VARIANT     232    232       G -> GN (in individuals from a malaria
FT                                endemic area in West Africa).
FT                                {ECO:0000269|PubMed:11668637}.
FT                                /FTId=VAR_017916.
FT   VARIANT     254    254       F -> L (in PG4D; type I;
FT                                dbSNP:rs142186404).
FT                                {ECO:0000269|PubMed:11950861}.
FT                                /FTId=VAR_017917.
FT   VARIANT     271    271       I -> T (in individuals from a malaria
FT                                endemic area in West Africa;
FT                                dbSNP:rs370072057).
FT                                {ECO:0000269|PubMed:11668637}.
FT                                /FTId=VAR_017918.
FT   VARIANT     386    386       R -> W (in dbSNP:rs148910227).
FT                                {ECO:0000269|Ref.7}.
FT                                /FTId=VAR_071161.
FT   VARIANT     413    413       I -> L (in PG4D; type I;
FT                                dbSNP:rs121918035).
FT                                {ECO:0000269|PubMed:11950861}.
FT                                /FTId=VAR_017919.
FT   VARIANT     470    470       T -> I (in dbSNP:rs200771788).
FT                                {ECO:0000269|Ref.7}.
FT                                /FTId=VAR_071162.
FT   MUTAGEN     462    472       SYCACRSKTIK->AAAAAAAAAAA: No effect on
FT                                cell surface location. Loss of oxLDL-
FT                                induced NF-kappa-B activation.
FT                                {ECO:0000269|PubMed:20037584}.
FT   MUTAGEN     463    463       Y->A: No effect on cell surface location.
FT                                Loss of oxLDL-induced NF-kappa-B
FT                                activation. Loss of complex formation
FT                                with TLR4 and TLR6.
FT                                {ECO:0000269|PubMed:20037584}.
FT   MUTAGEN     464    464       C->S: No effect on cell surface location,
FT                                nor on oxLDL-induced NF-kappa-B
FT                                activation.
FT                                {ECO:0000269|PubMed:20037584}.
FT   MUTAGEN     469    472       KTIK->ATIA: Abolishes ubiquitination
FT                                induced by lipids. Enhances fatty acid
FT                                uptake. {ECO:0000269|PubMed:18353783,
FT                                ECO:0000269|PubMed:21610069}.
FT   CONFLICT     44     44       L -> R (in Ref. 4; AAD13993).
FT                                {ECO:0000305}.
FT   CONFLICT    238    238       Y -> D (in Ref. 4; AAD13993).
FT                                {ECO:0000305}.
FT   CONFLICT    374    374       E -> Q (in Ref. 3; AAA16068 and 13; AA
FT                                sequence). {ECO:0000305}.
FT   HELIX        38     41       {ECO:0000244|PDB:5LGD}.
FT   STRAND       42     45       {ECO:0000244|PDB:5LGD}.
FT   HELIX        49     55       {ECO:0000244|PDB:5LGD}.
FT   STRAND       61     71       {ECO:0000244|PDB:5LGD}.
FT   HELIX        73     79       {ECO:0000244|PDB:5LGD}.
FT   STRAND       83     96       {ECO:0000244|PDB:5LGD}.
FT   STRAND      101    106       {ECO:0000244|PDB:5LGD}.
FT   TURN        107    110       {ECO:0000244|PDB:5LGD}.
FT   STRAND      111    117       {ECO:0000244|PDB:5LGD}.
FT   STRAND      120    122       {ECO:0000244|PDB:5LGD}.
FT   HELIX       124    126       {ECO:0000244|PDB:5LGD}.
FT   STRAND      127    129       {ECO:0000244|PDB:5LGD}.
FT   STRAND      134    138       {ECO:0000244|PDB:5LGD}.
FT   HELIX       140    148       {ECO:0000244|PDB:5LGD}.
FT   HELIX       152    164       {ECO:0000244|PDB:5LGD}.
FT   STRAND      169    174       {ECO:0000244|PDB:5LGD}.
FT   HELIX       175    180       {ECO:0000244|PDB:5LGD}.
FT   HELIX       187    189       {ECO:0000244|PDB:5LGD}.
FT   STRAND      208    215       {ECO:0000244|PDB:5LGD}.
FT   HELIX       221    223       {ECO:0000244|PDB:5LGD}.
FT   STRAND      227    230       {ECO:0000244|PDB:5LGD}.
FT   STRAND      233    235       {ECO:0000244|PDB:5LGD}.
FT   STRAND      237    240       {ECO:0000244|PDB:5LGD}.
FT   HELIX       241    244       {ECO:0000244|PDB:5LGD}.
FT   STRAND      251    253       {ECO:0000244|PDB:5LGD}.
FT   STRAND      263    268       {ECO:0000244|PDB:5LGD}.
FT   TURN        269    272       {ECO:0000244|PDB:5LGD}.
FT   STRAND      273    285       {ECO:0000244|PDB:5LGD}.
FT   STRAND      288    294       {ECO:0000244|PDB:5LGD}.
FT   HELIX       297    300       {ECO:0000244|PDB:5LGD}.
FT   TURN        303    305       {ECO:0000244|PDB:5LGD}.
FT   HELIX       307    312       {ECO:0000244|PDB:5LGD}.
FT   TURN        317    323       {ECO:0000244|PDB:5LGD}.
FT   STRAND      326    329       {ECO:0000244|PDB:5LGD}.
FT   HELIX       331    333       {ECO:0000244|PDB:5LGD}.
FT   TURN        334    336       {ECO:0000244|PDB:5LGD}.
FT   STRAND      339    342       {ECO:0000244|PDB:5LGD}.
FT   HELIX       344    346       {ECO:0000244|PDB:5LGD}.
FT   HELIX       351    354       {ECO:0000244|PDB:5LGD}.
FT   STRAND      357    359       {ECO:0000244|PDB:5LGD}.
FT   HELIX       364    367       {ECO:0000244|PDB:5LGD}.
FT   STRAND      370    373       {ECO:0000244|PDB:5LGD}.
FT   TURN        375    377       {ECO:0000244|PDB:5LGD}.
FT   STRAND      379    393       {ECO:0000244|PDB:5LGD}.
FT   HELIX       400    402       {ECO:0000244|PDB:5LGD}.
FT   STRAND      409    421       {ECO:0000244|PDB:5LGD}.
FT   HELIX       424    433       {ECO:0000244|PDB:5LGD}.
SQ   SEQUENCE   472 AA;  53053 MW;  543E748259A094FA CRC64;
     MGCDRNCGLI AGAVIGAVLA VFGGILMPVG DLLIQKTIKK QVVLEEGTIA FKNWVKTGTE
     VYRQFWIFDV QNPQEVMMNS SNIQVKQRGP YTYRVRFLAK ENVTQDAEDN TVSFLQPNGA
     IFEPSLSVGT EADNFTVLNL AVAAASHIYQ NQFVQMILNS LINKSKSSMF QVRTLRELLW
     GYRDPFLSLV PYPVTTTVGL FYPYNNTADG VYKVFNGKDN ISKVAIIDTY KGKRNLSYWE
     SHCDMINGTD AASFPPFVEK SQVLQFFSSD ICRSIYAVFE SDVNLKGIPV YRFVLPSKAF
     ASPVENPDNY CFCTEKIISK NCTSYGVLDI SKCKEGRPVY ISLPHFLYAS PDVSEPIDGL
     NPNEEEHRTY LDIEPITGFT LQFAKRLQVN LLVKPSEKIQ VLKNLKRNYI VPILWLNETG
     TIGDEKANMF RSQVTGKINL LGLIEMILLS VGVVMFVAFM ISYCACRSKT IK
//
